Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 4
2007 1
2008 4
2009 11
2010 3
2011 6
2012 11
2013 10
2014 13
2015 18
2016 25
2017 31
2018 31
2019 30
2020 22
2021 27
2022 34
2023 22
2024 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

283 results

Results by year

Filters applied: . Clear all
Page 1
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.
Lopez M, Crompot E, Josselin E, Farina A, Rubis M, Castellano R, Fares J, Wehbe M, Collette Y, Charafe E, Blanchin S, Romagne F, Pálfi A, Hechler T, Pahl A, Azim HA Jr, Lhospice F, Mamessier E, Bertucci F, Elands J, Préville X, Olive D. Lopez M, et al. Among authors: olive d. Cancer Res Commun. 2024 Nov 1;4(11):2998-3012. doi: 10.1158/2767-9764.CRC-24-0176. Cancer Res Commun. 2024. PMID: 39440991 Free PMC article.
BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signaling.
Kerneur C, Foucher E, Guillén Casas J, Colazet M, Le KS, Fullana M, Bergot E, Audemard C, Drapeau M, Louche P, Gorvel L, Rouvière MS, Boucherit N, Audebert S, Magrini E, Carnevale S, de Gassart A, Madakamutil L, Mantovani A, Garlanda C, Agaugué S, Cano CE, Olive D. Kerneur C, et al. Among authors: olive d. Cell Rep. 2024 Oct 22;43(10):114773. doi: 10.1016/j.celrep.2024.114773. Epub 2024 Sep 25. Cell Rep. 2024. PMID: 39325623 Free article.
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud AI, Hamid O, Larkin J, Yao L, Singh R, Lal R, Robert C. Long GV, et al. Among authors: gaudy marqueste c. Ann Oncol. 2024 Dec;35(12):1191-1199. doi: 10.1016/j.annonc.2024.08.2330. Epub 2024 Sep 15. Ann Oncol. 2024. PMID: 39306585 Clinical Trial.
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis.
Le Floch AC, Imbert C, Boucherit N, Gorvel L, Fattori S, Orlanducci F, Le Roy A, Archetti L, Crescence L, Panicot-Dubois L, Dubois C, Vey N, Briantais A, Anastasio A, Cano C, Guittard G, Frechin M, Olive D. Le Floch AC, et al. Among authors: guittard g, olive d. Cancer Immunol Res. 2024 Dec 3;12(12):1677-1690. doi: 10.1158/2326-6066.CIR-23-0868. Cancer Immunol Res. 2024. PMID: 39302336
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C-finding treated with midostaurin.
Heiblig M, Gourguechon C, Guilpain P, Bulai-Livideanu C, Barete S, Chantran Y, Agopian J, Brenet F, Dubreuil P, Lespinasse J, Lemal R, Tournilhac O, Terriou L, Launay D, Bouillet L, Chatain C, Damaj G, Ballul T, Greco C, Polivka L, Frenzel L, Meni C, Bouktit H, Benabou D, Gaudy-Marqueste C, Gousseff M, Le Mouel E, Neel A, Ranta D, Jaussaud R, Molina TJ, Bruneau J, Villarese P, Lhermitte L, Maouche-Chrétien L, Temple M, Kosmider O, Javier RM, Pelletier F, Castelain F, Retornaz F, Cabrera Q, Zunic P, Gourin MP, Wierzbicka-Hainaut E, Viallard JF, Lavigne C, Hoarau C, Durieu I, Dimicoli-Salazar S, Torregrosa-Diaz JM, Wemeau M, Soria A, Arock M, Bodemer C, Lortholary O, Hermine O, Rossignol J. Heiblig M, et al. Among authors: gaudy marqueste c. Am J Hematol. 2024 Nov;99(11):2127-2139. doi: 10.1002/ajh.27478. Epub 2024 Sep 17. Am J Hematol. 2024. PMID: 39287048
Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis.
Rossignol J, Georgin-Lavialle S, Canioni D, Beganovic O, Brouzes C, Fain O, Heiblig M, Gourguechon C, Guilpain P, Bulai-Livideanu C, Barete S, Agopian J, Brenet F, Dubreuil P, Lemal R, Tournilhac O, Terriou L, Launay D, Bouillet L, Chatain C, Damaj G, Ballul T, Greco C, Polivka L, Frenzel L, Meni C, Bouktit H, Benabou D, Devin C, Gaudy-Marqueste C, Gousseff M, Le Mouel E, Neel A, Ranta D, Jaussaud R, Jo Molina T, Bruneau J, Javier RM, Pelletier F, Castelain F, Retornaz F, Cabrera Q, Zunic P, Gourin MP, Wierzbicka-Hainaut E, Viallard JF, Lavigne C, Hoarau C, Durieu I, Dimicoli-Salazar S, Torregrosa-Diaz JM, Duval A, Garcelon N, Lespinasse J, Soria A, Chantran Y, Arock M, Bodemer C, Lortholary O, Asnafi V, Hermine O, Lhermitte L. Rossignol J, et al. Among authors: gaudy marqueste c. Haematologica. 2024 Aug 29. doi: 10.3324/haematol.2024.285740. Online ahead of print. Haematologica. 2024. PMID: 39219498 Free article.
Enhancing natural killer cells proliferation and cytotoxicity using imidazole-based lipid nanoparticles encapsulating interleukin-2 mRNA.
Delehedde C, Ciganek I, Bernard PL, Laroui N, Da Silva CC, Gonçalves C, Nunes J, Bennaceur-Griscelli AL, Imeri J, Huyghe M, Even L, Midoux P, Rameix N, Guittard G, Pichon C. Delehedde C, et al. Among authors: guittard g, nunes j. Mol Ther Nucleic Acids. 2024 Jun 26;35(3):102263. doi: 10.1016/j.omtn.2024.102263. eCollection 2024 Sep 10. Mol Ther Nucleic Acids. 2024. PMID: 39104868 Free PMC article.
283 results